Edward Shanbrom, M.D., F.A.C.P.; Martha Hainski, Ph.D.; John Payne, B.A.
This content is PDF only. Please click on the PDF icon to access.
Existing intramuscular gamma globulin preparations cannot provide immediate replacement therapy by infusion of large doses. Previous attempts to produce an intravenous gamma globulin by acid treatment or enzyme hydrolysis have resulted in preparations containing undesirable fragmented or aggregated molecules. The newly developed intravenous gamma globulin is a 3% protein concentration that is free of aggregates or anticomplementary activity. Clinical trials were conducted on 21 patients with acquired hypogammaglobulinemia secondary to lymphoma or leukemia. Four other patients with congenital hypogammaglobulinemia received single monthly injections to maintain "normal" gamma globulin levels. Severe infections were complications in the majority of patients. Doses of
Shanbrom E, Hainski M, Payne J. Clinical Evaluation of a New Intravenous Gamma Globulin.. Ann Intern Med. ;72:812. doi: 10.7326/0003-4819-72-5-812_1
Download citation file:
Published: Ann Intern Med. 1970;72(5):812.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use